A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay
Timon Seeger(Heidelberg University), Joseph C. Wu(Cardiovascular Institute of the South), Jae-Cheol Lee(Samsung (South Korea)), Wesley L. McKeithan(MACOM (United States)), Mark Mercola(Cardiovascular Institute of the South), Matthew T. Wheeler(Stanford University), Alexa Wnorowski(Cardiovascular Institute of the South), Angelos Oikonomopoulos(Cardiovascular Institute of the South), Edward Lau(University of Colorado Denver), Rajani Shrestha(MACOM (United States)), Huaxiao Yang(Cardiovascular Institute of the South), Caressa Chen(MACOM (United States)), Euan A. Ashley(Stanford University), Ioannis Karakikes(Cardiovascular Institute of the South), Chi Keung Lam(Hospital Authority), Fan Yang(Tianjin Medical University Cancer Institute and Hospital), Soah Lee(Sungkyunkwan University), George McMullen(Stanford University), Matthew Greenhaw(Cardiovascular Institute of the South)
Cited by 124
Related Papers
COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives
|Nature Reviews Cardiology|2020|1.5k
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy
|Circulation|2018|837
Wnt antagonism initiates cardiogenesis in <i>Xenopus laevis</i>
|Genes & Development|2001|482